SEARCH

SEARCH BY CITATION

References

  • 1
    Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol 2003; 72: 4352.
  • 2
    Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients – risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 10428.
  • 3
    Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 14653.
  • 4
    Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato MPI. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 9439.
  • 5
    Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG, SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366: 6019.
  • 6
    Kuderer NM, Ortel TL, Francis CW. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 2009; 27: 490211.
  • 7
    Nieswandt B, Hafner M, Echtendacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295300.
  • 8
    Schaffner F, Versteeg HH, Schillert A, Yokota N, Petersen LC, Mueller BM, Ruf W. Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development. Blood 2010; 116: 610613.
  • 9
    van den Berg YW, van den Hengel LG, Myers HR, Ayachi O, Jordanova E, Ruf W, Spek CA, Reitsma PH, Bogdanov VY, Versteeg HH. Alternatively spliced tissue factor induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA 2009; 106: 19497502.
  • 10
    Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2008; 111: 1909.
  • 11
    Collen A, Smorenburg SM, Peters E. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000; 60: 6196200.
  • 12
    Amirkhosravi A, Mousa SA, Amaya M, Francis JL. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003; 1: 19726.
  • 13
    Elias EG, Shukla SK, Mink IB. Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer 1975; 36: 12936.
  • 14
    Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C, Mornet M, Brun J, Hurdebourcq JP, Lemarie E. Subcutaneous heparin treatment increases survival in small cell lung cancer ‘Petites Cellules’ Group. Cancer 1994; 74: 3845.
  • 15
    Wereldsma JC, Bruggink ED, Meijer WS, Roukema JA, van Putten WL. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I). Cancer 1990; 65: 42532.
  • 16
    Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, Cetin M, Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2: 126671.
  • 17
    Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007; 5: 72937.
  • 18
    Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 6924.
  • 19
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 112.
  • 20
    Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002; 359: 61418.
  • 21
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 17788.
  • 22
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 153958.
  • 23
    Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M, Williamson RC. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 19448.
  • 24
    Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G, Büller HR. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 21305.
  • 25
    Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, Malkin MG, Sawaya R, Baker R, Falanga A, Parpia S, Finch T, Levine MN. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. Thromb Haemost 2010; 8: 195965.
  • 26
    Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, Dakhil SR, Levitt R, Alberts SR, Morton RF, Rowland KM, Novotny PJ, Loprinzi CL. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 2006; 81: 75867.
  • 27
    van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol 2011; 29: 20716.
  • 28
    Lecumberri R, López Vivanco G, Font A, González Billalabeitia E, Gúrpide A, Gómez Codina J, Isla D, Galán A, Bover I, Domine M, Vicente V, Rosell R, Rocha E. Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study. Thromb Res 2013; 132: 66670.
  • 29
    Auer R, Scheer A, Wells PS, Boushey R, Asmis T, Jonker D, Carrier M. The use of extended perioperative low molecular weight heparin (tinzaparin) to improve disease-free survival following surgical resection of colon cancer: a pilot randomized controlled trial. Blood Coagul Fibrinolysis 2011; 22: 7602.
  • 30
    Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, Melzer N, Kakkar AK, TOPIC Investigators. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012; 18: 15965.
  • 31
    Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48: 128392.
  • 32
    Massuti B, Lecumberri R, Lopez-Vivanco GM, Font A, Gonzalez-Billalabeitia E, Marti-Ciriquian JL, Gómez-Codina J, Domine M, Bover I, Isla D, Galan A, Gurpide A, Vicente V, Rosell R, Monreal M, Rocha E. ABEL trial: a phase II randomized trial adding bemiparin (B) to chemo-radiotherapy (CT-RT) in limited-stage small cell lung cancer (SCLC) – Final results. J Clin Oncol 2012; 30: Abstract 7095.
  • 33
    Riess H, Pelzer U, Opitz B, Stauch M, Reitzig P, Hahnfeld S, Müller L, Stieler J, Dörken B, Oettle H. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial. J Clin Oncol 2010:28: Abstract 4033.
  • 34
    Meyer G, Besse B, Friard S, Girard P, Corbi P, Azarian R, Monnet I, Alifano M, Chouaid C, Descourt R, Dennewald G, Taillade L, De Luca K, Giraud F, Pichon E, Chatellier G. Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours. Rev Mal Respir 2011; 28: 6549.
  • 35
    Kakkar VV, Balibrea JL, Martínez-González J, Prandoni P, CANBESURE Study Group. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010; 8: 12239.
  • 36
    Sakon M, Kobayashi T, Shimazui T. Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study. Thromb Res 2010; 125: 6570.
  • 37
    Griffiths GO, Burns S, Noble SI, Macbeth FR, Cohen D, Maughan TS. FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer 2009; 9: 355.
  • 38
    Buller HR, Prins MH. Late breaking clinical trial: the effect of the low-molecular-weight heparin nadroparin on the survival in patients with cancer: a randomized trial (for the IMPACT investigators). J Thromb Haemost 2009; 7: Abstract LBMO-004.
  • 39
    Yates J, Uberoi J, Sawczuk I, Golombos D, Gross M, Munver R. Evaluation of the safety of perioperative enoxaparin administration in patients undergoing robotic-assisted laparoscopic radical prostatectomy. J Endourol 2009; 23: A11516.
  • 40
    Weber C, Merminod T, Herrmann FR, Zulian GB. Prophylactic anti-coagulation in cancer palliative care: a prospective randomised study. Support Care Cancer 2008; 16: 84752.
  • 41
    Derlatka P, Benke M, Bidzinski M. Fibrinolysis and inhibitors of coagulation in patients with subclinical renal failure undergoing chemotherapy for advanced cervical cancer. Ginekol Onkolog 2007; 5: 15977.
  • 42
    Karthaus M, Kretzschmar A, Kröning H, Biakhov M, Irwin D, Marschner N, Slabber C, Fountzilas G, Garin A, Abecasis NG, Baronius W, Steger GG, Südhoff T, Giorgetti C, Reichardt P. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006; 17: 28996.
  • 43
    Tsimafeyeu I, Madzhuga A, Demidov L, Somonova O, Kharkevich G, Yelizarova A, Petenko N. Low molecular weight heparin (LMWH) increases the efficacy of immunotherapy in metastatic renal cell carcinoma patients with abnormal coagulation. J Clin Oncol 2007; 25: Abstract 15591.
  • 44
    Mak E, Townsley C, Buckman R, Chen E, Lopez L, Wang L, Moore M, Oza AM. Randomized phase II trial of capecitabine versus capecitabine, low molecular weight heparin, and prednisone in refractory colorectal carcinoma. J Clin Oncol 2009; 27: Abstract 15126.
  • 45
    Isikdogan A, Kaplan MA, Zincircioglu SB, Cit M, Cil T, Karadayi B, Dirier A, Kucukoner M, Inal A, Yildiz I. Concurrent chemoradiotherapy with or without low molecular weight heparin (LWMH) in the treatment of locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2010; 28: Abstract 17526.
  • 46
    Kakkar AK, Doval DC, Fareed J, Kerr D, Maganji JM, Mueller I. Rationale and design of the GASTRANOX trial on a low-molecular-weight heparin [LMWH], enoxaparin, with chemotherapy vs. chemotherapy alone in inoperable gastric and gastro-oesophageal cancer. Ann Oncol 2010; 21: Abstract 808P.
  • 47
    Vadhan-Raj S, Zhou X, Varadhachary GR, Milind J, Fogelman D, Shroff R, Bueso-Ramos CE, Nguyen M, Wang X, Wolff RA, Abbruzzese JL, Overman MJ. Randomized controlled trial of dalteparin for primary thromboprophylaxis for venous thromboembolism (VTE) in patients with advanced pancreatic cancer (APC): risk factors predictive of VTE. Blood 2013; 122: Abstract 580.
  • 48
    Di NM, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2012; 2: CD008500.
  • 49
    Che DH, Cao JY, Shang LH, Man YC, Yu Y. The efficacy and safety of low-molecular-weight heparin use for cancer treatment: a meta-analysis. Eur J Intern Med 2013; 24: 4339.
  • 50
    Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003; 23: 211015.
  • 51
    ClinicalTrials.gov. US National Institutes of Health; c2014. Extended Peri-operative Tinzaparin to Improve Disease-free Survival in Patients With Resectable Colon Cancer (PERIOP-01); 2011 October 18 [updated 2012 November]; [about 6 screens]. http://clinicaltrials.gov/show/NCT01455831. Accessed 3 November 2013.